Review



monoclonal mouse anti human c9 neoantigen  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Hycult Biotech monoclonal mouse anti human c9 neoantigen
    Monoclonal Mouse Anti Human C9 Neoantigen, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse anti human c9 neoantigen/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    monoclonal mouse anti human c9 neoantigen - by Bioz Stars, 2025-06
    94/100 stars

    Images



    Similar Products

    monoclonal mouse anti human c9 neoantigen  (Hycult Biotech)
    94
    Hycult Biotech monoclonal mouse anti human c9 neoantigen
    Monoclonal Mouse Anti Human C9 Neoantigen, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse anti human c9 neoantigen/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    monoclonal mouse anti human c9 neoantigen - by Bioz Stars, 2025-06
    94/100 stars
    		  Buy from Supplier
    tcc, human, mab ae11  (Hycult Biotech)
    94
    Hycult Biotech tcc, human, mab ae11
    Tcc, Human, Mab Ae11, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tcc, human, mab ae11/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    tcc, human, mab ae11 - by Bioz Stars, 2025-06
    94/100 stars
    		  Buy from Supplier
    mab mouse anti human c9 neoantigen  (Hycult Biotech)
    94
    Hycult Biotech mab mouse anti human c9 neoantigen
    Mab Mouse Anti Human C9 Neoantigen, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mab mouse anti human c9 neoantigen/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    mab mouse anti human c9 neoantigen - by Bioz Stars, 2025-06
    94/100 stars
    		  Buy from Supplier
    mouse anti tcc ae11  (Hycult Biotech)
    94
    Hycult Biotech mouse anti tcc ae11

    Mouse Anti Tcc Ae11, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti tcc ae11/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    mouse anti tcc ae11 - by Bioz Stars, 2025-06
    94/100 stars
    		  Buy from Supplier
    mouse anti human c5b 9  (Hycult Biotech)
    94
    Hycult Biotech mouse anti human c5b 9

    Mouse Anti Human C5b 9, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human c5b 9/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    mouse anti human c5b 9 - by Bioz Stars, 2025-06
    94/100 stars
    		  Buy from Supplier
    mouse anti human c5b 9 fitc  (Hycult Biotech)
    92
    Hycult Biotech mouse anti human c5b 9 fitc
    ( A–C ) CHC coating of PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. Uncoated and CHC-coated PAEC were treated for 4 hrs with 10% human plasma, and assessed by ELISA for ( A ) the deposition of activated complement <t>C5b-9</t> and ( B ) the expression of the adhesion molecule E-selectin ( B ). ( C ) Supernatants from this assay were measured for D-dimers concentration. CHC coating significantly protected WT PAEC. Uncoated GTKO.hCD46.hTBM PAEC were significantly protected compared to uncoated WT PAEC; coating with CHC further reduced complement deposition and cellular activation, although this was not statistically significant. ( D,F ) CHC coating of hTNFα-activated PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. WT and GTKO.hCD46.hTBM PAEC were treated with hTNFα (100 ng/ml) for 2 hrs to induce cellular activation and shedding of the endothelial glycocalyx. After, PAEC were coated with CHC and incubated for 4 hrs with 10% human plasma, and assessed for ( D ) complement C5b-9 deposition and ( E ) endothelial E-selectin expression as well as ( F ) D-dimer levels in the supernatants. CHC coating significantly protected hTNFα-activated WT and GTKO.hCD46.hTBM PAEC compared to uncoated PAEC. Significance was measured by one-way ANOVA with Bonferroni correction (*p < 0.05, **p < 0.01, ***p < 0.001). Data are mean ± SD of three independent experiments.
    Mouse Anti Human C5b 9 Fitc, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human c5b 9 fitc/product/Hycult Biotech
    Average 92 stars, based on 1 article reviews
    mouse anti human c5b 9 fitc - by Bioz Stars, 2025-06
    92/100 stars
    		  Buy from Supplier
    c5b 9 tcc ae11 mouse mab dako  (Agilent technologies)
    86
    Agilent technologies c5b 9 tcc ae11 mouse mab dako
    ( A–C ) CHC coating of PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. Uncoated and CHC-coated PAEC were treated for 4 hrs with 10% human plasma, and assessed by ELISA for ( A ) the deposition of activated complement <t>C5b-9</t> and ( B ) the expression of the adhesion molecule E-selectin ( B ). ( C ) Supernatants from this assay were measured for D-dimers concentration. CHC coating significantly protected WT PAEC. Uncoated GTKO.hCD46.hTBM PAEC were significantly protected compared to uncoated WT PAEC; coating with CHC further reduced complement deposition and cellular activation, although this was not statistically significant. ( D,F ) CHC coating of hTNFα-activated PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. WT and GTKO.hCD46.hTBM PAEC were treated with hTNFα (100 ng/ml) for 2 hrs to induce cellular activation and shedding of the endothelial glycocalyx. After, PAEC were coated with CHC and incubated for 4 hrs with 10% human plasma, and assessed for ( D ) complement C5b-9 deposition and ( E ) endothelial E-selectin expression as well as ( F ) D-dimer levels in the supernatants. CHC coating significantly protected hTNFα-activated WT and GTKO.hCD46.hTBM PAEC compared to uncoated PAEC. Significance was measured by one-way ANOVA with Bonferroni correction (*p < 0.05, **p < 0.01, ***p < 0.001). Data are mean ± SD of three independent experiments.
    C5b 9 Tcc Ae11 Mouse Mab Dako, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5b 9 tcc ae11 mouse mab dako/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    c5b 9 tcc ae11 mouse mab dako - by Bioz Stars, 2025-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Journal: iScience

    Article Title: The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery

    doi: 10.1016/j.isci.2021.103215

    Figure Lengend Snippet:

    Article Snippet: Mouse anti-TCC (aE11) , Hycult , Cat#HM2167-1MG.

    Techniques: Purification, Recombinant, Binding Assay, Blocking Assay, Staining, Enzyme-linked Immunosorbent Assay, Multiplex Assay, Software, Cytometry

    ( A–C ) CHC coating of PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. Uncoated and CHC-coated PAEC were treated for 4 hrs with 10% human plasma, and assessed by ELISA for ( A ) the deposition of activated complement C5b-9 and ( B ) the expression of the adhesion molecule E-selectin ( B ). ( C ) Supernatants from this assay were measured for D-dimers concentration. CHC coating significantly protected WT PAEC. Uncoated GTKO.hCD46.hTBM PAEC were significantly protected compared to uncoated WT PAEC; coating with CHC further reduced complement deposition and cellular activation, although this was not statistically significant. ( D,F ) CHC coating of hTNFα-activated PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. WT and GTKO.hCD46.hTBM PAEC were treated with hTNFα (100 ng/ml) for 2 hrs to induce cellular activation and shedding of the endothelial glycocalyx. After, PAEC were coated with CHC and incubated for 4 hrs with 10% human plasma, and assessed for ( D ) complement C5b-9 deposition and ( E ) endothelial E-selectin expression as well as ( F ) D-dimer levels in the supernatants. CHC coating significantly protected hTNFα-activated WT and GTKO.hCD46.hTBM PAEC compared to uncoated PAEC. Significance was measured by one-way ANOVA with Bonferroni correction (*p < 0.05, **p < 0.01, ***p < 0.001). Data are mean ± SD of three independent experiments.

    Journal: Scientific Reports

    Article Title: Surface modification of pig endothelial cells with a branched heparin conjugate improves their compatibility with human blood

    doi: 10.1038/s41598-017-04898-w

    Figure Lengend Snippet: ( A–C ) CHC coating of PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. Uncoated and CHC-coated PAEC were treated for 4 hrs with 10% human plasma, and assessed by ELISA for ( A ) the deposition of activated complement C5b-9 and ( B ) the expression of the adhesion molecule E-selectin ( B ). ( C ) Supernatants from this assay were measured for D-dimers concentration. CHC coating significantly protected WT PAEC. Uncoated GTKO.hCD46.hTBM PAEC were significantly protected compared to uncoated WT PAEC; coating with CHC further reduced complement deposition and cellular activation, although this was not statistically significant. ( D,F ) CHC coating of hTNFα-activated PAEC reduces complement deposition, cellular activation and coagulation induced by human plasma. WT and GTKO.hCD46.hTBM PAEC were treated with hTNFα (100 ng/ml) for 2 hrs to induce cellular activation and shedding of the endothelial glycocalyx. After, PAEC were coated with CHC and incubated for 4 hrs with 10% human plasma, and assessed for ( D ) complement C5b-9 deposition and ( E ) endothelial E-selectin expression as well as ( F ) D-dimer levels in the supernatants. CHC coating significantly protected hTNFα-activated WT and GTKO.hCD46.hTBM PAEC compared to uncoated PAEC. Significance was measured by one-way ANOVA with Bonferroni correction (*p < 0.05, **p < 0.01, ***p < 0.001). Data are mean ± SD of three independent experiments.

    Article Snippet: Rabbit anti-human C3b/c FITC (A0062; Dako), mouse anti-human C5b-9 FITC (clone aE11; HM2167F, Hycult Biotech), and mouse anti-human CD62E FITC (clone 1.2B6, MCA883F, AbD Serotec) were diluted in PBS/1% BSA and incubated for 60 min at RT followed by three washes.

    Techniques: Activation Assay, Coagulation, Enzyme-linked Immunosorbent Assay, Expressing, Concentration Assay, Incubation